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Introduction. Triple negative breast cancer (TNBC) is biologically aggressive and is associated with a worse prognosis. To
understand the impact of race/ethnicity on outcome for patients with TNBC, confounding factors such as socioeconomic status
(SES) need to be controlled. We examined the impact of race/ethnicity on a cohort of patients of low SES who have TNBC.
Methods. 786 patients with Stage 0–III breast cancer were evaluated. Of these, 202 patients had TNBC (26%). Primary endpoints
were cancer recurrence and death. ZIP code-based income tract and institutional ﬁnancial data were used to assess SES. Data were
analyzed using Kaplan-Meier survival analysis, log-rank tests, Cox Proportional hazard regression, chi square test, and t-tests. A P
value ≤0.05 was considered statistically signiﬁcant. Results. Of the 468 African-Americans (60%) in the database, 138 had TNBC;
64 of 318 Caucasians had TNBC. 80% of patients had an annual income of ≤$20,000. The 5-year overall survival was 77% for
African-American women versus 72% for Caucasian women (P = 0.95). On multivariate analysis, race/ethnicity had an impact
on disease-free survival (P = 0.027) but not on overall survival (P = 0.98). Conclusion. In a predominantly indigent population,
race/ethnicity had no impact on overall survival for patients with triple negative breast cancer.
1.Introduction
Breast cancer is the most frequently diagnosed cancer in
women and is associated with substantial morbidity and
mortality. Breast cancer is a heterogeneous disease with dif-
ferent subtypes that are based upon the expression level
of estrogen receptor (ER), progesterone receptor (PR), and
HER-2/neureceptor (HER-2) [1].Triple-negative breastcan-
cers (TNBC), are breast tumors characterized by lack of ex-
pression of estrogen (ER), progesterone (PR), and HER2neu
receptors and comprise 15% of all breast cancers. Most
TNBC have a basal-like molecular phenotype by gene ex-
pression proﬁling [2, 3]. TNBC also shares clinical and
pathologic features with hereditary BRCA1-related breast
cancers including lack of ER/PR and HER2neu, presence of
p53 mutation, basal gene expression patterns, and BRCA1
inactivation by either mutation or pathway dysfunction [4–
6]. Most of these tumors are high grade or poorly differen-
tiated tumors [7, 8]. TNBC has been shown to be associated
with a poorer prognosis compared to receptor positive breast
cancer subtype [9]. TNBC is not responsive to hormonal
therapies such as Tamoxifen and aromatase inhibitors nor
to inhibitors of HER-2 such as trastuzumab. Whether the
poorer outcome with TNBC is the result of the loss of these
therapeutic options or is the result of a more aggressive tu-
mor biology or both is unknown.
African-American women have higher breast cancer
death rates compared to Caucasian women, despite having
a lower incidence of breast cancer [10]. Based on the 2001–
2005 data from the Louisiana Tumor Registry, breast cancer
mortality was 25.3% for Caucasian females and 40.9% for
African-American females. The causes for this disparity in
outcomes are not known. Some investigators believe that
socioeconomic factors play a signiﬁcant role in breast cancer
disparities,whileothersspeculatethatitisthebiologicdiﬀer-
ences that play a central role in outcome disparities. TNBC
has been demonstrated to be more prevalent among young
African-American females when compared to Caucasian2 International Journal of Breast Cancer
women and is the basis for the argument in favor of biology
as the culprit for breast cancer disparities. However, many
of these studies do not adequately control for socioeconomic
status (SES). Possibly related to SES is the observation that
AfricanAmerican womenarelesslikely tobe diagnosed atan
early stage when treatment can improve survival. Additional
other potentially SES-related factors that may contribute to
the survival diﬀerence include unequal access to medical
care, health insurance status, treatment noncompliance, and
socioeconomic status [11].
Louisiana State University Health Sciences Center in
Shreveport (LSUHSC-S) is a public hospital and is unique
in that the majority of the patients treated are uninsured
or receive Medicaid and are of low socioeconomic status.
We have previously demonstrated that at LSUHSC-S overall
survival of breast cancer patients is similar between African-
American and Caucasian women when controlled for SES.
However, this study did not speciﬁcally evaluate whether
such parity of outcome occurred in the subset of patients
with TNBC. Our current study is aimed to address the fol-
lowing question: among patients with TNBC whoare of sim-
ilar socioeconomic status and given equal access to medical
care, does the survival disparity between the racial/ethnic
groups still exist?
2. Methods
A prospectively maintained breast cancer database was cre-
ated in 1998. Details of this database have previously been
reported [12]. Brieﬂy, patients with stage 0 to 3 breast can-
cer who were treated before October 2008 were accrued
and analyzed. We obtained approval to conduct the study
from our Institutional Review Board. Of the 803 breast
cancer patients in the database, we excluded 17 patients
because of the patients belonging to other ethnicities (His-
panics or Asians) or having incomplete data. Of the re-
maining 786 patients, 468 patients were African-Americans
and 318 patients were Caucasians. Triple-negative breast
cancers (TNBCs) are deﬁned as tumors that lack estrogen,
progesterone, and HER-2 expressions. We identiﬁed 202
patients (25.7%) with TNBC. The majority of patients
(∼90%) were treated at FWCC/LSUHSC-S and the remain-
ingpatientsweretreatedatasafety-nethospital,theEACon-
way Hospital, a sister public hospital managed by LSUHSC-
S. The American Joint Committee on Cancer (AJCC) 6th
Edition was used to stage patients [13].
Two Society-of-Surgical-Oncology-(SSO) fellowship
trained surgical oncologists performed the surgeries at
FWCC/LSUHSC-S. Three general surgeons, each of whom
had more than 10 years of surgical experience, per-
formed surgeries at E. A. Conway Hospital. A weekly multi-
disciplinary tumor board conference was held to discuss
all breast cancer cases performed for the previous week.
Discussion of care of patients treated at E. A. Conway was
conducted via telemedicine conferencing. Attendants of the
weekly tumor board included a myriad of specialists (sur-
gical oncologists, medical oncologists, radiation oncologists,
radiologists, geneticists, residents, fellows, nurses, research-
ers, coordinators, and educators).
All treatment and surveillance protocols were standard-
ized in order to ensure study homogeneity. All patients were
oﬀered standard treatment protocols for adjuvant and neo-
adjuvant chemotherapy and radiation therapy. Antiestrogen
therapyandherceptinwerenotusedinthiscohort.Deﬁnitive
surgeries included either breast conservation therapy (BCT,
lumpectomy with tumor-free margin, sentinel lymph node
dissection and/or axillary lymph node dissection, and breast
irradiation) or a mastectomy (±axillary lymph node dissec-
tion in select cases). After BCT, fractionated megavoltage
external beam irradiation (encompassing the whole breast)
to a total dose of 50Gy/25 fractions was administered using
tangential treatment portals; the supraclavicular area is irra-
diated (to the same total dose) when indicated (i.e., presence
of disease to four or more axillary lymph nodes). Adjuvant
systemic chemotherapy was oﬀered and administered as
indicated per current standard of care.
Patient follow-up consisted of a history and physical ex-
amination every 3 months for 3 years, every 6 months for
years 4 and 5, and annually thereafter. A chest X-ray, mam-
mogram,completebloodcount,andliverfunctiontestswere
obtained annually. Additional radiologic and/or histologic
evaluation was performed based on clinical indications.
Clinical data were accrued and recorded prospectively and
included age at diagnosis, comorbid conditions, stage of dis-
ease, treatment protocol, surveillance protocol compliance,
cancer recurrence, and death. Compliance with treatment
and surveillance protocols was over 90%.
Socioeconomic statuses were assigned to each patient
basedontwosources:theInternalRevenueService2001ZIP-
code-based income tract and the LSU Hospital Computer
Service database. These sources did not diﬀer between the
two racial/ethnic groups and the data were not combined
acrossmethods.TheInternalRevenueService2001ZIP-code
based income tract reports income as median annual income
(MAI) per ZIP code stratiﬁed into quintiles based on ten
thousand dollar increments. If the percentage of patients
falls within 1% of either stratiﬁcation group, the average
of both groups was used to estimate the MAI. Because the
2001 tax year approximates the middle of dates of surgery for
our patient population, the data from 2001 was chosen. All
patients were assigned an MAI and stratiﬁed accordingly.
Our hospital Computer Services database was used to
link patients’ ﬁnancial code with their names, medical record
numbers,initialdatesofdiagnosis,andICD-9diagnosiscode
174.0–174.9. These ﬁnancial codes were then used to stratify
patients into the following subsets: commercial insurance,
Medicare, Medicaid, or indigent/free care. Because this da-
tabase only tracks patients for the past 7 years, only 57% of
patients (115) were identiﬁed from this database.
The impact of race/ethnicity on the outcome of patients
with TNBC breast cancers was assessed by comparing out-
comes between Caucasian and African-American women.
Asian and Hispanic women comprised less than 5 patients in
ourlargedatabaseandthereforewereexcludedfromanalysis.
Clinical outcomes were then compared to ﬁve reports on
outcome for patients with TNBC (Table 4)[ 1, 8, 14–16].
All statistical analyses were performed using MedCalc
software (Microsoft, Inc.). The chi-square test was used toInternational Journal of Breast Cancer 3
Table 1: Distribution of patient, clinicopathologic, and socioeconomic characteristics of 202 Patients with triple negative breast cancer.
African-American Caucasian P value
(N = 138) (N = 64)
68% 32%
Characteristics
Mean age years (range) 54 (28–33) 60 (36–87) 0.38
Mean tumor size (cm) 3.39 3.16 0.35
Tumor size distribution
T1 (28%) 33 (24%) 24 (38%)
T2 (53%) 76 (55%) 30 (47%) 0.25
T3 (13%) 19 (14%) 7 (11%)
T4 (6%) 10 (7%) 3 (4%)
Nodal distribution
N0 (55%) 71 (51%) 40 (62%)
N1 (25%) 37 (27%) 14 (22%) 0.5
N2 (15%) 23 (17%) 7 (11%)
N3 (5%) 7 (5%) 3 (5%)
Stage distribution
Stage 1 (21%) 25 (18%) 17 (26%)
Stage 2 (52%) 73 (53%) 33 (52%) 0.31
Stage 3 (27%) 40 (29%) 14 (22%)
Tumor grade
I/II (38%) 40/125 (32%) 29/59 (49%) 0.04
III (62%) 85/125 (68%) 30/59 (51%)
Deﬁnitive surgery
Breast-conserving Rx (31%) 51 (37%) 12 (19%) 0.01
Mastectomy (69%) 87 (63%) 52 (81%)
Systemic treatment
Adriamycin alone (19%) 28 (20%) 11 (17%)
Adriamycin + Taxane (41%) 60 (44%) 22 (34%)
Taxane alone (3%) 3 (2%) 3 (5%) 0.33
Hormone therapy alone (3%) 2 (1%) 3 (5%)
Hormone therapy + chemotherapy (16%) 19 (14%) 14 (22%)
Others (18%) 26 (19%) 11 (17%)
Median annual income $16,493 $16,667
Mean (range) annual income $17,873 $21,081 <0.001
($15,367–$36,772) ($15,795–$36,787)
Financial class
Commercial (11%) 8/80 (10%) 5/35 (14%)
Medicare (10%) 7/80 (9%) 4/35 (11%) 0.69
Medicaid (6%) 6/80 (7%) 1/35 (3%)
Free care (73%) 59/80 (74%) 25/35 (72%)
analyze categorical data, and the independent samples t-test
was used to compare means. Disease-free survival (DFS)
was calculated from the date of surgery to the date of ﬁrst
recurrence (local or distant) or date of last follow-up. Overall
survival (OS) was calculated from the date of surgery to the
date of death from any cause or date of last follow-up.
The Kaplan-Meier survival method and the log-rank test
were used to generate and compare survival curves. The Cox
proportional hazard regression model was used to perform
multivariate analyses. Risk ratios and 95% conﬁdence inter-
vals (CI) were calculated from the model. A P value ≤0.05
was considered statistically signiﬁcant.
3. Results
Two-hundred and two patients with TNBC were iden-
tiﬁed. This represents approximately 26% (202/786) of
all patients in our database. Table 1 demonstrates patient,4 International Journal of Breast Cancer
clinicopathologic, and socioeconomic characteristics of our
cohort. There were 138 African-American women (68%)
and 64 Caucasian women (32%) with TNBC representing
29% (138/468) of the African-American women and 20%
(64/318) of the total number of Caucasian women in our
database.Themeanageatdiagnosiswas54yearsforAfrican-
American women and 60 years for Caucasian women (P =
0.38), and the mean follow-up time was 52.8 months.
The median annual income by ZIPcode for the entire
group of patients with TNBC was $16,577 (range, $15,367
to $36,788). The median annual income was $16,493 (range:
$15,367 to $36,772) for African-American women and
was $16,667 (range: $15,795 to $36,787) for Caucasian
women. The diﬀerences between the median incomes were
statistically signiﬁcant (P<0.001) although the magnitude
of such diﬀerences does not appear to be clinically relevant.
All patients resided within geographical areas with reported
median annual incomes of $40,000 or less, and approxi-
mately 90% (181/202) were in areas with a reported median
annual income of less than or equal to $30,000. The ﬁnancial
data at the time of diagnosis indicated no diﬀerence in the
percent of patients with commercial insurance, Medicare,
Medicaid, or free care (Table 1).
Of all the clinicopathologic parameters examined, only
tumor grade (P = 0.0 4 ) ,t y p eo fd e ﬁ n i t i v eo p e r a t i o n
(P = 0.01), and median annual income (P<0.001) were
signiﬁcantly diﬀerent between the two racial/ethnic groups.
Mean age at diagnosis (P = 0.38), mean tumor size (P =
0.35), tumor size distribution (P = 0.25), nodal distribution
(P = 0.50), stage distribution (P = 0.31), receipt of ad-
juvant therapy (P = 0.33), and ﬁnancial class distribution
(P = 0.69) were not signiﬁcantly diﬀerent between the two
racial/ethnic groups (Table 1).
Overall, locoregional recurrences occurred in 13.8% (28
of 202 patients) of patients. The locoregional recurrence rate
for African-American women was 20% (13/64) for Cauca-
sian women (P = 0.08). Additionally, 41/202 (20.3%) of
the entire TNBC cohort died by the time of last follow-up
(December 2009) with a mortality rate of 20% (28/138) for
African-American women and 20% (13/64) for Caucasian
women (P = 0.85).
To discern the impact of race/ethnicity on the outcome
for patients with TNBC, we evaluated OS and DFS between
African-American and Caucasian women (Figures 1 and 2).
Inourpreviousstudies,wedemonstratedthatneitherOSnor
DFS was signiﬁcantly diﬀerent between the two racial/ethnic
groups, speciﬁcally in a large cohort of 786 patients with
stage 0–3 breast cancers and a cohort of 375 patients with
ER-negative tumors. Within the ER-negative tumors, we
were able to identify a signiﬁcant proportion of patients to
have TNBC (54%). Therefore, this cohort was evaluated
separately.
Similar to our previous ﬁndings, in the subgroup of
women with TNBC, we found no statistically signiﬁcant dif-
ference in DFS or OS between the two racial/ethnic groups.
The 5-year DFS was 66% for African-American women and
50% for Caucasian women; the median DFS was 99 months
for African-American women and 60 months for Caucasian
women (P = 0.16) (Figure 1) .T h e5 - y e a rO Sw a s7 7 %f o r
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Figure 1: Eﬀect of race/ethnicity on disease-free survival for 202
patients with triple-receptor negative breast cancer: shown is the
DFS for 202 African-American and Caucasian patients with TNBC
as described in section 2. The 5-year DFS was 66% for African-
American women and 50% for Caucasian women (P = 0.16).
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Figure 2:Eﬀectofrace/ethnicityonoverallsurvivalfor202patients
with triple-receptor negative breast cancer: shown is the OS for 202
African-American and Caucasian patients with TNBC as described
in section 2. The 5-year OS was 77% for African-American women
and 72% for Caucasian women (P = 0.95).
African-American women and 72% for Caucasian women;
the median OS was 138 months for African-American wom-
en and 64 months for Caucasian women (P = 0.95) (Figure
2).
The Cox proportional hazard model was used to com-
pare race/ethnicity, age at diagnosis, tumor grade, median
income, T-stage, and N-stage for risk of cancer recurrence
and overall survival (Tables 2 and 3). Note that although
race/ethnicity was an independent predictor for DFS (P =
0.027), it was not an independent predictor for OS (P =
0.98). Clinical independent predictors for DFS were T-stage
(P = 0.001)andN-stage(P = 0.05).OnlyN-stage(P = 0.01)
was an independent predictor for OS.
Suboptimal results run the risk of masking any potential
signiﬁcant diﬀerences in outcomes between African-Ameri-
can women and Caucasian women. Therefore, we compared
our outcomes for women with TNBC with outcomes re-
ported in the literature [1, 8, 14–16]. In selected publishedInternational Journal of Breast Cancer 5
Table 2: Eﬀect of race/ethnicity on cancer recurrence for patients
with triple-receptor-negative breast cancer (Cox proportional haz-
ard model).
Relative Risk 95% CI P value
Race/ethnicity 1.84 1.07 to 3.14 0.027
Age at diagnosis 1.00 0.98 to 1.03 0.80
Grade 1.20 0.71 to 2.03 0.49
Income level 0.87 0.54 to 1.40 0.58
T-stage 1.68 1.22 to 2.30 0.001
N-stage 1.29 1.0 to 1.68 0.05
Table 3:Eﬀectofrace/ethnicityonoverallsurvivalforpatientswith
triple-receptor negative breast cancer (Cox proportional hazard
model).
Relative risk 95% CI P value
Race/ethnicity 1.00 0.48 to 2.06 0.98
Age at diagnosis 1.01 0.98 to 1.05 0.41
Grade 1.89 0.89 to 3.97 0.09
Income level 1.15 0.63 to 2.09 0.65
T-stage 1.43 0.95 to 2.17 0.09
N-Stage 1.53 1.09 to 2.16 0.01
Table 4: Comparison of clinical outcomes for patients with triple-
receptor negative breast cancer.
Overall survival (%) Disease free survival (%)
Chu (FWCC) 75 60; 66(AA), 50 (C)
Haﬀty 80 72
Bauer 77 —
Kyndi 50 (high-risk cohort) —
Lund 59.6 30.8
Dawood 71 (3-yr OS) 68 (AA), 62 (C)
FWCC: Feist-Weiller Cancer Center, AA: African-american, and C: Cau-
casian.
series, the 5-year OS rate ranges from 59.6% to 80% and
the 5-year DFS rate ranges from 30.8% to 72%. Our ﬁgures
compare favorably with these historic ﬁgures (Table 4).
4. Discussion
African-American women have a lower incidence of breast
cancer but a higher breast cancer mortality rate when com-
pared to Caucasian women [17–19]. Such disparity has been
the focus of recent debates. Confounding variables make it
diﬃcult to establish the exact nature of such disparity. While
some investigators attribute it to diﬀerences in income and
social status, which aﬀect access to and receipt of treatment,
othersaccreditittoracial/ethnicdiﬀerencesintumorbiology
and responsiveness to treatment [10–12, 14, 17, 18, 20–23].
Race/ethnicity as an independent predictor of survival in
breast cancer has been reported in several studies, although
most do not adequately control for socioeconomic status
(SES) and/or tumor subtype (i.e., TNBC) [16].
In our initial study of 786 patients with operable breast
cancer(stage0–III),wedemonstratedthatrace/ethnicityhad
no impact on outcome when equal access was rendered,
regardless of patients’ ﬁnancial statuses. In that study, out-
comes at LSUHSC-S rivaled those reported by the National
Cancer Data Base (NCDB). These results were achieved in a
population that has historically been associated with poorer
outcomes; over two-thirds of our patients were classiﬁed as
having either Medicaid or free care and the median annual
income for both groups was less than $17,000 [12].
A potential confounder of the above study was an imbal-
ance of the diﬀerent breast cancer subtypes between African-
American and Caucasian women. We noted that African-
American women had a signiﬁcantly higher proportion of
ER-negative tumors than Caucasian women. To address this,
we separately evaluated outcomes for 375 patients with ER-
negative breast cancers to determine whether there was dis-
parity between the two racial/ethnic groups [11]. However,
similar to the results of our initial study, we found that there
were no signiﬁcant diﬀerences in breast cancer mortality
rates between African-American and Caucasian women who
had ER-negative tumors [11]. Again, these results were
achieved in a relatively homogenous cohort of patients with
low SES.
One of the limitations of our ER-negative study was
that it did not delineate the proportion of patients who
had TNBC. TNBC is used by clinicians in reference to the
basal-like subtype of breast cancer although only 85% of
TNBCs are basal-like. Numerous studies have shown that
TNBC is associated with a decreased overall survival when
compared to receptor-positive tumors and that TNBC is
more prevalent among African American women [24]. This
fact has popularly been thought of as being one of the major
contributors of disparity in outcomes between African-
American women and Caucasian women [24]. However, our
results demonstrated that even within the TNBC cohorts
race/ethnicity had no impact on outcome. These results
were obtained despite African-American women having had
a signiﬁcantly higher tumor grade than Caucasian women
(grade 3 = 68% versus 51%; P = 0.04) and that TNBC was
more predominant among African-American women than
Caucasian women.
The principle that race/ethnicity should have no impact
on outcome for patients with TNBC was further reinforced
by a study by Dawood et al. [8]. In this study of nearly 500
patients who were treated with primary systemic chemother-
apy followed by deﬁnitive surgery, neither pathologic com-
plete response rates (pCR) nor survival outcomes diﬀer
between the two racial/ethnic groups [8].
The ﬁve-year overall survival rate for all breast cancer
subtypes is approximately 89% and this rate drops precipi-
tously for patients with TNBC (77% to 80%) [1, 16]. Our
data seemed to support these results. What is unique about
our cohort is that we were able to control for socioeconomic
status and receipt of systemic therapy, thus eliminating any
potential socioeconomic biases.
Based on our previous and current data and ﬁndings,
we can conclude that disparity in survival between African-
American females and Caucasian females can be mitigated6 International Journal of Breast Cancer
when all patients are provided with the same standard of
care breast cancer treatment. This paradigm seems to be
applicable for wide variety of breast cancer, including those
with TNBC. In addition, our data do not support the idea
of biological diﬀerences in tumor subtypes between com-
pared and African-Americans. The higher proportion of
younger African-Americans developing TNBCs compared
with Caucasians may still contribute to the overall worse
outcomes, even though the responses to treatment are
similar.
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